Biogen Australia

20 PBAC submissions on file, active 2016–2025. 80% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Nusinersen
  Neurology · Recommended with restriction · 2023—
• Natalizumab
  Neurology · Recommended · 2025other sponsor
• Daclizumab
  Neurology · Recommended with restriction · 2016—
• Dimethyl fumarate
  Neurology · Recommended with restriction · 2019—
• Omaveloxolone
  Rare disease · Not recommended · 2025—
• Diroximel fumarate
  Neurology · Recommended with restriction · 2022—
• Tofersen
  Neurology · Recommended with restriction · 2025—

Therapy area mix

Activity by year

2016 (3) · 2017 (1) · 2018 (2) · 2019 (3) · 2020 (2) · 2021 (1) · 2022 (3) · 2023 (2) · 2025 (3)

Rejection patterns

Across 2 Not recommended decisions on file.

• 1×clinical claim not supported by data presented (non-randomised
• 1×non-controlled trial with no comparator arm
• 1×unreliable indirect comparison with multiple transitivity issues
• 1×uncertain applicability to older patients and those with 1 SMN2 copy)
• 1×economic model overly simplistic and unfit for purpose with uncertain magnitude of QALY gain